8.36 USD
+0.22 (+2.7%)
At close: Feb 10, 2026
8.21 USD
-0.15 (-1.79%)
After Hours: 2/10/2026, 8:01:26 PM
ChartMill assigns a Buy % Consensus number of 82% to DMAC. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 15.81. This target is 89.11% above the current price.
- DMAC was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about DMAC.
- In the previous month the buy percentage consensus was at a similar level.
- DMAC was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-18 | Lake Street | Maintains | Buy -> Buy |
| 2025-07-18 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-07-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-07 | HC Wainwright & Co. | Initiate | Buy |
| 2024-08-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-06-22 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-07-07 | Lake Street | Maintains | Buy |
| 2022-07-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-07-07 | Craig-Hallum | Maintains | Buy |
| 2021-06-30 | Roth Capital | Maintains | Buy |
| 2021-04-08 | Oppenheimer | Initiate | Outperform |
| 2021-02-17 | Roth Capital | Initiate | Buy |
DIAMEDICA THERAPEUTICS INC / DMAC FAQ
What is the average price target for DIAMEDICA THERAPEUTICS INC (DMAC) stock?
11 analysts have analysed DMAC and the average price target is 15.81 USD. This implies a price increase of 89.11% is expected in the next year compared to the current price of 8.36.
What is the consensus rating for DMAC stock?
The consensus rating for DIAMEDICA THERAPEUTICS INC (DMAC) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed DIAMEDICA THERAPEUTICS INC (DMAC)?
The number of analysts covering DIAMEDICA THERAPEUTICS INC (DMAC) is 11.